PDF) Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
4.6
$ 15.00
In stock
(420)
Product Description
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease
PDF) The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms
Meeting abstracts from the 10th International Conference on cGMP: Generators, Effectors and Therapeutic Implications, Journal of Translational Medicine
The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease
Soluble guanylate cyclase activator BAY 54–6544 improves vasomotor function and survival in an accelerated ageing mouse model - Ataei Ataabadi - 2022 - Aging Cell - Wiley Online Library
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
Frontiers The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications
